Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Achillion Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Achillion has developed a platform based on Zinc Finger Targeting, a technology for directing drugs against viral sites that do not mutate and may therefore be less prone to becoming drug resistant. The company aims to produce novel therapies for HIV, hepatitis and other viruses. To balance the risks associated with exploiting such a nascent technology, Achillion has licensed several Yale University anti-viral compounds, one of which is already in the clinic.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts